Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Oteseconazole (VT-1161): Selective Candida CYP51 Inhibitor
2026-08-17
Oteseconazole, also called VT-1161, is a tetrazole CYP51 inhibitor with potent in vitro activity against multiple Candida species. Its fungal-enzyme selectivity and clinical use for prevention of recurrent vulvovaginal candidiasis make it a useful translational antifungal research compound, while its weak activity against Aspergillus fumigatus defines an important boundary.
-
MEDUSA Reveals Hidden Mechanisms of Drug-Induced Death
2026-08-17
Honeywell and colleagues introduce MEDUSA, a simulation-assisted framework that separates drug-induced changes in cell growth from changes in cell death during pooled functional-genomic screens. Applied to DNA damage responses, the method revealed that p53 loss redirects lethality from apoptosis toward a respiration-dependent nonapoptotic death program, illustrating how time-resolved modeling can improve interpretation of chemo-genetic data.
-
Chemoproteomic Inhibitors of SLC15A4
2026-08-16
Chiu and colleagues used integrated chemical proteomics to develop functional small-molecule inhibitors of the endolysosomal transporter SLC15A4, a regulator of TLR and NOD signaling. The study connects target engagement with pathway suppression across immune-cell systems, animal models, and lupus patient samples, providing a framework for evaluating SLC15A4 as a druggable autoimmune target.
-
VX-765: A Causal Tool for Caspase-1 Biology
2026-08-15
VX-765 and its active metabolite VRT-043198 provide a practical way to dissect caspase-1-driven cytokine processing and pyroptosis. This guide goes beyond routine assay optimization by showing how to interpret selectivity, prodrug behavior, and cross-model evidence without overstating mechanism.
-
Lysosomal β-Galactosidase Staining Kit in HNSCC
2026-08-14
Use K2181 to visualize lysosomal acidic β-galactosidase activity in HNSCC cells and tissue sections without confusing a control stain with proof of senescence. Its polystyrene-compatible workflow, chromogenic readout, and defined troubleshooting logic support reproducible cisplatin-resistance experiments.
-
Urolithin A Workflows for Mitochondrial Research
2026-08-14
Build reproducible Urolithin A assays around mitophagy, mitochondrial respiration, and gene-expression endpoints rather than relying on a single viability readout. This practical workflow also shows how to test mitochondrial-metabolic hypotheses in hepatic stellate cells without overstating evidence from fibrosis research.
-
FAISL Stabilizes FAK Through Calpain-2 in TNBC
2026-08-13
The reference study identifies FAISL as a long noncoding RNA that preserves focal adhesion kinase by preventing calpain-2-mediated proteolysis. Its findings connect lncRNA-dependent control of FAK protein stability with triple-negative breast cancer adhesion, growth, and metastasis, while also illustrating why protease regulation should be evaluated alongside kinase signaling.
-
Recombinant Human IL-15: Assays and Applications
2026-08-13
Build reproducible T-cell, NK-cell, and cytokine-response assays with a tag-free, high-purity Interleukin-15 reagent. This workflow also shows how immune-cell measurements can complement, but not replace, circuit-level studies of early life adversity and innate defensive behavior.
-
NLRP3 Astrocyte Remodeling in Morphine Tolerance
2026-08-12
Yuan et al. identify NLRP3 inflammasome activation as a mechanistic link between repeated morphine exposure and a shift toward an A1-like reactive astrocyte profile. The study combines behavioral, molecular, and spatial measurements to show that MCC950 slows tolerance development while normalizing inflammatory and astrocyte phenotype markers.
-
Pam3CSK4 TFA in Translational TLR1/2 Research
2026-08-12
A mechanistic and strategic guide to using Pam3CSK4 TFA as a standardized TLR1/2 agonist for innate immune profiling, inflammatory modeling, and translational maternal-neonatal research.
-
PEDV Replication Depends on IMPDH-Driven Nucleotide Supply
2026-08-11
The reference study combines untargeted metabolomics with IMPDH2 knockdown and merimepodib treatment to show that porcine epidemic diarrhea virus (PEDV) depends on host guanine nucleotide biosynthesis. Its cell-type comparison and orthogonal validation identify IMPDH as a host-directed antiviral target while clarifying the metabolic basis of PEDV replication.
-
Recombinant Human IL-15 in Neuroimmune Research
2026-08-11
Early life adversity research identifies oxytocin signaling in the superior colliculus as a regulator of innate defensive behavior. This thought-leadership perspective explains how Recombinant Human IL-15 can support carefully bounded immune-cell experiments that test, rather than assume, neuroimmune links.
-
Extrahepatic mRNA Delivery with Virus-Mimicking Particles
2026-08-10
The reference study introduces a self-assembling enveloped virus-mimicking particle that combines engineered RNA-binding peptides with programmable phospholipid envelopes to overcome the hepatic bias of many mRNA delivery systems. Its lung and spleen targeting results, together with IL-12 mRNA activity in a metastatic lung tumor model, provide a useful framework for evaluating extrahepatic cytokine delivery while highlighting the need for further translational validation.
-
PBA-Modified PAD4 Inhibitors Suppress Tumor NETs
2026-08-09
The reference study developed phenylboronic acid-modified PAD4 inhibitors, identifying Compound 5i as a tumor-targeted agent that suppresses the PAD4–H3cit–NET axis. Across sarcoma and breast cancer models, the compound reduced tumor growth and metastasis while producing a favorable safety and immune-microenvironment profile.
-
CLCC1 and Herpesvirus Nuclear Egress Fusion
2026-08-08
A 2024 bioRxiv preprint identifies the host protein CLCC1 as essential for membrane fusion during herpes simplex virus 1 nuclear egress, distinguishing this step from viral NEC-driven budding. The findings connect herpesvirus capsid export with nuclear pore membrane insertion and provide a mechanistic basis for studying host-dependent stages of viral replication.